[go: up one dir, main page]

IL149392A0 - PEPTIDE ANALOGS AND MIMETICS SUITABLE FOR IN VIVO USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL PROTEIN FOLDING INTO AMYLOID, AMYLOID-LIKE DEPOSITS OR β-SHEET RICH PATHOLOGICAL PRECURSOR THEREOF - Google Patents

PEPTIDE ANALOGS AND MIMETICS SUITABLE FOR IN VIVO USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL PROTEIN FOLDING INTO AMYLOID, AMYLOID-LIKE DEPOSITS OR β-SHEET RICH PATHOLOGICAL PRECURSOR THEREOF

Info

Publication number
IL149392A0
IL149392A0 IL14939200A IL14939200A IL149392A0 IL 149392 A0 IL149392 A0 IL 149392A0 IL 14939200 A IL14939200 A IL 14939200A IL 14939200 A IL14939200 A IL 14939200A IL 149392 A0 IL149392 A0 IL 149392A0
Authority
IL
Israel
Prior art keywords
amyloid
deposits
precursor
treatment
diseases associated
Prior art date
Application number
IL14939200A
Original Assignee
Axonyx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axonyx Inc filed Critical Axonyx Inc
Publication of IL149392A0 publication Critical patent/IL149392A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL14939200A 1999-11-05 2000-11-04 PEPTIDE ANALOGS AND MIMETICS SUITABLE FOR IN VIVO USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL PROTEIN FOLDING INTO AMYLOID, AMYLOID-LIKE DEPOSITS OR β-SHEET RICH PATHOLOGICAL PRECURSOR THEREOF IL149392A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16391199P 1999-11-05 1999-11-05
PCT/US2000/030416 WO2001034631A2 (en) 1999-11-05 2000-11-04 PEPTIDE ANALOGS AND MIMETICS SUITABLE FOR IN VIVO USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL PROTEIN FOLDING INTO AMYLOID, AMYLOID-LIKE DEPOSITS OR β-SHEET RICH PATHOLOGICAL PRECURSOR THEREOF

Publications (1)

Publication Number Publication Date
IL149392A0 true IL149392A0 (en) 2002-11-10

Family

ID=22592138

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14939200A IL149392A0 (en) 1999-11-05 2000-11-04 PEPTIDE ANALOGS AND MIMETICS SUITABLE FOR IN VIVO USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL PROTEIN FOLDING INTO AMYLOID, AMYLOID-LIKE DEPOSITS OR β-SHEET RICH PATHOLOGICAL PRECURSOR THEREOF

Country Status (11)

Country Link
EP (1) EP1286590A4 (en)
JP (1) JP2004513873A (en)
KR (2) KR20020079731A (en)
CN (1) CN1437442A (en)
AU (1) AU781044B2 (en)
BR (1) BR0015513A (en)
CA (1) CA2389041A1 (en)
EA (1) EA004739B1 (en)
IL (1) IL149392A0 (en)
MX (1) MXPA02004468A (en)
WO (1) WO2001034631A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8003612B2 (en) 1997-10-08 2011-08-23 Proteotech Inc. Small peptides for the treatment of Alzheimer's disease and other beta-amyloid protein disorders
DE10101430B4 (en) * 2001-01-13 2008-10-02 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Soluble cyclic analogues for the modulation of amyloidogenesis
AU2004203461B2 (en) * 2002-01-31 2009-09-03 Tel Aviv University Future Technology Development L.P. Peptides Antibodies Directed Thereagainst and Methods Using Same for Diagnosing and Treating Amyloid-Associated Diseases
US20040052928A1 (en) 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
DE10230141B4 (en) * 2002-07-04 2004-07-15 Priontype Gmbh Method and kit for the enrichment and detection of modified prion proteins (PrPSc)
JP2006508904A (en) * 2002-07-08 2006-03-16 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ β-sheet breaking peptide
US20060281686A1 (en) * 2002-12-02 2006-12-14 Lopez Areiza John J Aza-peptides
EP2719394B1 (en) * 2003-06-30 2015-07-29 Tel Aviv University Future Technology Development L.P. Peptides for treating amyloid-associated diseases
EP1765858B1 (en) * 2004-06-17 2012-11-21 Mannkind Corporation Epitope analogs
CA2599291C (en) * 2005-02-28 2013-12-31 Alphabeta Ab Compounds for reducing aggregation of amyloid beta-peptide
WO2006122408A1 (en) 2005-05-18 2006-11-23 Aegera Therapeutics Inc. Bir domain binding compounds
EP1746422A1 (en) * 2005-07-19 2007-01-24 Universita'degli Studi Di Milano Method for the identification of proteins folding inhibitors
WO2008015384A1 (en) * 2006-08-04 2008-02-07 Lonza Biologics Plc Method for predicting protein aggregation and designing aggregation inhibitors
WO2012066549A1 (en) 2010-11-15 2012-05-24 Ramot At Tel-Aviv University Ltd. Dipeptide analogs for treating conditions associated with amyloid fibril formation
SG187271A1 (en) * 2011-07-07 2013-02-28 Agency Science Tech & Res Anti-amyloidogenic, alpha-helix breaking ultra-small peptide therapeutic
HUE032237T2 (en) * 2011-08-17 2017-09-28 Ironwood Pharmaceuticals Inc Treatment of gastrointestinal disorders
DE102013016002A1 (en) 2013-09-26 2015-03-26 Forschungszentrum Jülich GmbH Cyclic amyloid beta-binding peptides and their use
EP3049099B1 (en) * 2013-09-26 2020-06-17 Forschungszentrum Jülich GmbH Amyloid-beta-binding peptides and the use thereof for the therapy and diagnosis of alzheimer's dementia
MY179462A (en) * 2013-10-11 2020-11-06 Malaysian Palm Oil Board Protective effects of oil palm composition on alzheimer?s disease
KR101627106B1 (en) 2014-03-26 2016-06-03 연세대학교 산학협력단 polypeptide having multiple directionality and self-assembled nanostructure containing the same
DE102015003676A1 (en) * 2015-03-20 2016-09-22 Forschungszentrum Jülich GmbH Fachbereich Patente Specifically A-beta species-binding peptides for the therapy and / or diagnosis of Alzheimer's dementia
AU2019271189A1 (en) 2018-05-15 2021-01-07 Lloyd Hung Loi TRAN Therapeutic agent composition and method of use, for treatment of mild cognitive impairment, depression, and psychological disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE218583T1 (en) * 1995-03-14 2002-06-15 Praecis Pharm Inc COMPOUNDS WITH AGGREGATION-MODULATING EFFECTS ON AMYLOID PROTEIN
US5948763A (en) * 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
AU741199B2 (en) * 1996-08-27 2001-11-22 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation comprising D-amino acids

Also Published As

Publication number Publication date
EA004739B1 (en) 2004-08-26
AU1463501A (en) 2001-06-06
AU781044B2 (en) 2005-05-05
KR20020079731A (en) 2002-10-19
CA2389041A1 (en) 2001-05-17
EA200200536A1 (en) 2002-12-26
WO2001034631A3 (en) 2002-12-27
KR20060133114A (en) 2006-12-22
JP2004513873A (en) 2004-05-13
WO2001034631A2 (en) 2001-05-17
EP1286590A4 (en) 2005-05-11
BR0015513A (en) 2004-07-06
CN1437442A (en) 2003-08-20
EP1286590A2 (en) 2003-03-05
MXPA02004468A (en) 2004-09-10

Similar Documents

Publication Publication Date Title
IL149392A0 (en) PEPTIDE ANALOGS AND MIMETICS SUITABLE FOR IN VIVO USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL PROTEIN FOLDING INTO AMYLOID, AMYLOID-LIKE DEPOSITS OR β-SHEET RICH PATHOLOGICAL PRECURSOR THEREOF
WO2002046222A3 (en) Compositions and methods for diagnosing alzheimer's disease
AU2003239531A8 (en) Protein cages for the delivery of medical imaging and therapy
GB0404693D0 (en) Pharmaceutical preparations for the treatment of ocular surface and other disorders
EP1578421A4 (en) Pharmaceutical preparations for treatments of diseases and disorders of the breast
IL171956A0 (en) Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
WO2003039454A3 (en) Beta-secretase inhibitors and methods of use
AU4541101A (en) Design and discovery of protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
HRP20030805A2 (en) Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
IL143699A0 (en) Use of polypeptides or nucleic acids for the diagnosis or treatment of skin disorders and wound healing and for the identification of pharmacologically active substances
DE50010284D1 (en) MEDICAMENT FOR THE TREATMENT OF BLOOD HIGH PRESSURE
IL148401A0 (en) Hsp70-derived peptides and uses thereof in the diagnosis and treatment of autoimmune diseases
DE50013843D1 (en) MEDICAMENT FOR THE TREATMENT OF DARMER DISEASES
PL357827A1 (en) Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations
AU2002212471A1 (en) Peptides for use in the treatment of alzheimer's disease
ZA97741B (en) Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders.
EP1377287A4 (en) Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases
GB9929497D0 (en) Improved amino acid mixtures for the treatment and/or management of certain diseases
GB2395903B (en) Dickkopf 5 gene, protein and antibodies: a role in the treatment and diagnosis of insulin-resistant states
IL155237A0 (en) Combination therapy for the treatment of estrogen-sensitive disease
LV12656B (en) Healing remedy and treatment for the treatment of opiate addiction patients
AU2001253886A1 (en) Methylxanthines in the diagnosis and treatment of autistic disorder
AU2002350751A8 (en) Compounds which can be used to diagnose and monitor diseases associated with the formation of amyloid protein fibrils
NO20034269L (en) Use of compounds with the biological activity of vasoactive intestinal peptide for the treatment of chronic obstructive pulmonary disease
GB0008326D0 (en) Diagnosis and treatment of autism and related disorders